دورية أكاديمية
Acute Effects of Single Versus Combined Inhaled β2-Agonists Salbutamol and Formoterol on Time Trial Performance, Lung Function, Metabolic and Endocrine Variables
| العنوان: | Acute Effects of Single Versus Combined Inhaled β2-Agonists Salbutamol and Formoterol on Time Trial Performance, Lung Function, Metabolic and Endocrine Variables |
|---|---|
| المؤلفون: | Bizjak, Daniel A., Nussbaumer, Dorle, Winkert, Kay, Treff, Gunnar, Takabajashi, Kensuke, Mentz, Lennart, Schober, Franziska, Buhl, Jasmine-Lèonike, Harps, Lukas C., Parr, Maria K. |
| سنة النشر: | 2023 |
| المجموعة: | FU Berlin: Refubium |
| مصطلحات موضوعية: | Anti-doping, Performance-enhancing methods, Beta 2 agonists, Muscle metabolism, Detection methods, Sex-specific thresholds, ddc:790 |
| الوصف: | Background High prevalence rates of β2-agonist use among athletes in competitive sports makes it tempting to speculate that illegitimate use of β2-agonists boosts performance. However, data regarding the potential performance-enhancing effects of inhaled β2-agonists and its underlying molecular basis are scarce. Methods In total, 24 competitive endurance athletes (12f/12m) participated in a clinical double-blinded balanced four-way block cross-over trial to investigate single versus combined effects of β2-agonists salbutamol (SAL) and formoterol (FOR), to evaluate the potential performance enhancement of SAL (1200 µg, Cyclocaps, Pb Pharma GmbH), FOR (36 µg, Sandoz, HEXAL AG) and SAL + FOR (1200 µg + 36 µg) compared to placebo (PLA, Gelatine capsules containing lactose monohydrate, Pharmacy of the University Hospital Ulm). Measurements included skeletal muscle gene and protein expression, endocrine regulation, urinary/serum β2-agonist concentrations, cardiac markers, cardiopulmonary and lung function testing and the 10-min time trial (TT) performance on a bicycle ergometer as outcome variables. Blood and urine samples were collected pre-, post-, 3 h post- and 24 h post-TT. Results Mean power output during TT was not different between study arms. Treatment effects regarding lung function (p < 0.001), echocardiographic (left ventricular end-systolic volume p = 0.037; endocardial global longitudinal strain p < 0.001) and metabolic variables (e.g. NR4A2 and ATF3 pathway) were observed without any influence on performance. In female athletes, total serum β2-agonist concentrations for SAL and FOR were higher. Microarray muscle gene analysis showed a treatment effect for target genes in energy metabolism with strongest effect by SAL + FOR (NR4A2; p = 0.001). Of endocrine variables, follicle-stimulating hormone (3 h Post–Post-TT), luteinizing hormone (3 h Post–Pre-TT) and insulin (Post–Pre-TT) concentrations showed a treatment effect (all p < 0.05). Conclusions No endurance performance-enhancing effect for SAL, ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | 15 Seiten; application/pdf |
| اللغة: | English |
| العلاقة: | https://refubium.fu-berlin.de/handle/fub188/41143Test; http://dx.doi.org/10.17169/refubium-40864Test |
| DOI: | 10.17169/refubium-40864 |
| DOI: | 10.1186/s40798-023-00630-3 |
| الإتاحة: | https://doi.org/10.17169/refubium-40864Test https://doi.org/10.1186/s40798-023-00630-3Test https://refubium.fu-berlin.de/handle/fub188/41143Test |
| حقوق: | https://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: | edsbas.C8BA96C8 |
| قاعدة البيانات: | BASE |
| DOI: | 10.17169/refubium-40864 |
|---|